Dahiyat launched Xencor’s biotherapeutic programs and protein design platform

Stylli brings record of success in drug development and technology commercialization

US Patent Issued for Novel G-CSF with Improved Pharmaceutical Properties Created by Protein Design Automation Technology

Xencor’s Protein Design Automation Technology Creates New Modality for Blocking TNF Alpha and Related Proteins

Chromos and Xencor announce agreement for use of the ACE System to produce biologics. Burnaby, British Columbia, Canada and Monrovia, California, United States – Chromos Molecular Systems Inc. (“Chromos“ TSX: CHR) and Xencor announced today that they have entered into a non-exclusive research

Bassil Dahiyat Named One of the World’s Top Young Innovators by Technology Review, MIT’s Magazine of Innovation. Dahiyat To Be Honored September 24-25 at The Emerging Technologies Conference at MIT

(BW Healthwire)–October 09, 2002—Grant to Support the Rational Design of Non-immunogenic Proteins

Xencor Reaches Research Milestone (BW Healthwire)–June 17, 2002—Monrovia, CA – Xencor today announced that it has reached a major milestone in its research agreement with Syngenta’s (NYSE: SYT) Torrey Mesa Research Institute (TMRI). In just six months, half the time agreed upon, Xencor has created

Enhancing The Therapeutic Utility of Biopharmaceuticals: The Next Frontier (BW Healthwire)–June 04, 2002—Xencor’s Vice President, Discovery Technologies, Robert Pacifici, Ph.D., Presents at BIO 2002, June 10 at 10:30 a.m.-12:00 p.m. in room 701A. Monrovia, CA – Xencor, a drug discovery company

(BW Healthwire)–May 29, 2002—Xencor’s Protein Design Technology Provides Superior Control and Flexibility in Biotherapeutic Creation